Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05184101




Registration number
NCT05184101
Ethics application status
Date submitted
6/01/2022
Date registered
11/01/2022
Date last updated
26/02/2024

Titles & IDs
Public title
Inhaled Heparin for Hospitalised Patients With Coronavirus Disease 2019 (COVID-19)
Scientific title
INHALEd Nebulised Unfractionated HEParin for the Treatment of Hospitalised Patients With COVID-19 (INHALE-HEP) Australia
Secondary ID [1] 0 0
INHALE-HEP Australia Version 3
Universal Trial Number (UTN)
Trial acronym
INHALE-HEP
Linked study record

Health condition
Health condition(s) or problem(s) studied:
COVID-19 0 0
Condition category
Condition code
Infection 0 0 0 0
Other infectious diseases
Respiratory 0 0 0 0
Other respiratory disorders / diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Unfractionated Heparin

Experimental: Nebulised heparin - Participants assigned to 'nebulised heparin' will receive nebulised heparin in addition to the standard care required as determined by the treating team.

No Intervention: Standard care - Participants assigned to 'standard care' will receive the standard care required as determined by the treating team and will not be treated with nebulised heparin.


Treatment: Drugs: Unfractionated Heparin
Heparin sodium will be administered as a nebulised aerosol dose of 25,000 IU heparin three times a day (TDS) via an Aerogen Solo (Aerogen, Ireland) vibrating mesh aerosol drug nebulizer.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Intubation
Timepoint [1] 0 0
28 days
Secondary outcome [1] 0 0
Mortality
Timepoint [1] 0 0
60 days
Secondary outcome [2] 0 0
Oxygenation
Timepoint [2] 0 0
28 days
Secondary outcome [3] 0 0
Length of hospitalisation
Timepoint [3] 0 0
60 days

Eligibility
Key inclusion criteria
- Age 18 years or older

- Currently admitted to hospital

- There is a positive sample for COVID-19 within the past 14 days. The sample can be a
nasal or pharyngeal swab, sputum, tracheal aspirate, bronchoalveolar lavage, or
another sample from the patient

- Requiring oxygenation according to the modified ordinal clinical scale 4-5
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Intubated and on mechanical ventilation, or requiring immediate intubation as per the
treating clinician's assessment

- Heparin allergy or heparin-induced thrombocytopaenia

- Activated partial thromboplastin time (APTT) > 120 seconds, not due to anticoagulant
therapy and does not correct with administration of fresh frozen plasma

- Platelet count < 20 x 10^9 per L within 48 hours of randomisation

- Pulmonary bleeding or uncontrolled bleeding within 48 hours of randomisation

- Known or suspected pregnancy

- Acute brain injury that may result in long-term disability

- Myopathy, spinal cord injury, or nerve injury or disease with a likely prolonged
incapacity to breathe independently e.g. Guillain-Barre syndrome

- Treatment limitations in place, i.e. not for intubation, not for ICU admission

- Death is imminent or inevitable within 24 hours

- Clinician objection

- Participant consent declined

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?


The people assessing the outcomes
Intervention assignment
Parallel
Other design features
Phase
Phase 2/Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Withdrawn
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
1/08/2023
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/03/2024
Actual
Sample size
Target
Accrual to date
Final
0
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
St George Hospital - Kogarah
Recruitment postcode(s) [1] 0 0
2217 - Kogarah

Funding & Sponsors
Primary sponsor type
Other
Name
Australian National University
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
The George Institute
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Other
Name [2] 0 0
St George Hospital, Australia
Address [2] 0 0
Country [2] 0 0
Other collaborator category [3] 0 0
Other
Name [3] 0 0
St Vincent's Hospital Melbourne
Address [3] 0 0
Country [3] 0 0
Other collaborator category [4] 0 0
Other
Name [4] 0 0
John Hunter Hospital
Address [4] 0 0
Country [4] 0 0
Other collaborator category [5] 0 0
Other
Name [5] 0 0
Royal North Shore Hospital
Address [5] 0 0
Country [5] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Investigator-initiated, multi-centre, randomised, open-label trial of nebulised heparin
sodium in addition to standard care compared to standard care alone in hospitalised patients
with COVID-19 infection.
Trial website
https://clinicaltrials.gov/ct2/show/NCT05184101
Trial related presentations / publications
van Haren FMP, Page C, Laffey JG, Artigas A, Camprubi-Rimblas M, Nunes Q, Smith R, Shute J, Carroll M, Tree J, Carroll M, Singh D, Wilkinson T, Dixon B. Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence. Crit Care. 2020 Jul 22;24(1):454. doi: 10.1186/s13054-020-03148-2.
van Haren FMP, Richardson A, Yoon HJ, Artigas A, Laffey JG, Dixon B, Smith R, Vilaseca AB, Barbera RA, Ismail TI, Mahrous RS, Badr M, De Nucci G, Sverdloff C, van Loon LM, Camprubi-Rimblas M, Cosgrave DW, Smoot TL, Staas S, Sann K, Sas C, Belani A, Hillman C, Shute J, Carroll M, Wilkinson T, Carroll M, Singh D, Page C. INHALEd nebulised unfractionated HEParin for the treatment of hospitalised patients with COVID-19 (INHALE-HEP): Protocol and statistical analysis plan for an investigator-initiated international metatrial of randomised studies. Br J Clin Pharmacol. 2021 Aug;87(8):3075-3091. doi: 10.1111/bcp.14714. Epub 2021 Jan 19.
Public notes

Contacts
Principal investigator
Name 0 0
Frank MP van Haren, PhD
Address 0 0
Australian National University
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT05184101